Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients
- PMID: 12936989
- PMCID: PMC182594
- DOI: 10.1128/AAC.47.9.2882-2887.2003
Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients
Abstract
Antimicrobial resistance is an emerging problem among nosocomial bacteria. Risk factors for the recovery of ceftriaxone-resistant (CRCF) or -susceptible (CSCF) Citrobacter freundii in clinical cultures from hospitalized patients were determined by using a case-case-control study design. CRCF was isolated from 43 patients (case group 1) and CSCF was isolated from 87 patients (case group 2) over a 3-year period. Risk factors for CRCF were exposure to imipenem (odds ratio [OR], 7.5; 95% confidence interval [CI], 1.2 to 45.4), broad-spectrum cephalosporins (OR, 6.9; 95% CI, 1.8 to 26.7), vancomycin (OR, 3.0; 95% CI, 1.2 to 7.4), or piperacillin-tazobactam (OR, 2.6; 95% CI, 1.1 to 6.2), as well as hospital length of stay >or=1 week (OR, 3.6; 95% CI, 1.3 to 10.2) and intensive care unit (ICU) stay (OR, 2.6; 95% CI, 1.1 to 6.2). Risk factors for CSCF were peripheral vascular disease (OR, 23.2; 95% CI, 4.3 to 124.6), AIDS (OR, 9.5; 95% CI, 1.6 to 55.5), cerebrovascular disease (OR, 4.2; 95% CI, 1.6 to 10.8), and ICU stay (OR, 3.1; 95% CI, 1.8 to 5.4).
Similar articles
-
A small outbreak of third generation cephem-resistant Citrobacter freundii infection on a surgical ward.Jpn J Infect Dis. 2004 Aug;57(4):181-2. Jpn J Infect Dis. 2004. PMID: 15329453 No abstract available.
-
Clinical features and antimicrobial susceptibility trends in Citrobacter freundii bacteremia.J Microbiol Immunol Infect. 2002 Jun;35(2):109-14. J Microbiol Immunol Infect. 2002. PMID: 12099331
-
Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.Antimicrob Agents Chemother. 2002 Mar;46(3):854-8. doi: 10.1128/AAC.46.3.854-858.2002. Antimicrob Agents Chemother. 2002. PMID: 11850272 Free PMC article.
-
Epidemiology of Citrobacter spp. infections among hospitalized patients: a systematic review and meta-analysis.BMC Infect Dis. 2024 Jul 2;24(1):662. doi: 10.1186/s12879-024-09575-8. BMC Infect Dis. 2024. PMID: 38956542 Free PMC article.
-
Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.Antimicrob Resist Infect Control. 2018 Jul 4;7:79. doi: 10.1186/s13756-018-0370-9. eCollection 2018. Antimicrob Resist Infect Control. 2018. PMID: 29997889 Free PMC article.
Cited by
-
Multidrug resistant citrobacter: an unusual cause of liver abscess.BMJ Case Rep. 2013 Apr 22;2013:bcr2013008714. doi: 10.1136/bcr-2013-008714. BMJ Case Rep. 2013. PMID: 23608848 Free PMC article.
-
Assessment of Airborne Bacterial and Fungal Communities in Selected Areas of Teaching Hospital, Kandy, Sri Lanka.Biomed Res Int. 2019 Jun 12;2019:7393926. doi: 10.1155/2019/7393926. eCollection 2019. Biomed Res Int. 2019. PMID: 31309114 Free PMC article.
-
Effects of reducing beta-lactam antibiotic pressure on intestinal colonization of antibiotic-resistant gram-negative bacteria.Intensive Care Med. 2010 Mar;36(3):512-9. doi: 10.1007/s00134-009-1714-y. Intensive Care Med. 2010. PMID: 19921150 Free PMC article. Clinical Trial.
-
Economic and health impact modelling of a whole genome sequencing-led intervention strategy for bacterial healthcare-associated infections for England and for the USA.Microb Genom. 2023 Aug;9(8):mgen001087. doi: 10.1099/mgen.0.001087. Microb Genom. 2023. PMID: 37555752 Free PMC article.
-
Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.Antimicrob Agents Chemother. 2006 Jun;50(6):2192-6. doi: 10.1128/AAC.00060-06. Antimicrob Agents Chemother. 2006. PMID: 16723582 Free PMC article.
References
-
- Arens, S., and L. Verbist. 1997. Differentiation and susceptibility of Citrobacter isolates from patients in a university hospital. Clin. Microbiol. Infect. 3:53-57. - PubMed
-
- Bonten, M. J., S. Slaughter, A. W. Ambergen, M. K. Hayden, J. van Voorhis, C. Nathan, and R. A. Weinstein. 1998. The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch. Intern. Med. 158:1127-1132. - PubMed
-
- Brown, E. H., R. C. Spencer, and J. M. Brown. 1990. The emergence of bacterial resistance in hospitals—a need for continuous surveillance. J. Hosp. Infect. 15(Suppl. A):35-39. - PubMed
-
- Burwen, D. R., S. N. Banerjee, and R. P. Gaynes. 1994. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance. Syst. J. Infect. Dis. 170:1622-1625. - PubMed
-
- Chen, Y. S., W. W. Wong, C. P. Fung, K. W. Yu, and C. Y. Liu. 2002. Clinical features and antimicrobial susceptibility trends in Citrobacter freundii bacteremia. J. Microbiol. Immunol. Infect. 35:109-114. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources